文献速递MDS 与骨髓增殖性肿瘤

三阴性原发性血小板增多症的突变谱与心血管危险因素影响预后

Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.
PubMed 文献 · Leukemia · 2026-07-13

该研究纳入241例经骨髓活检证实的三阴性原发性血小板增多症(TN-ET)患者,19.5%检出致病/可能致病变异。突变携带者年龄更大、既往血栓史更多,且与白血病进展和总生存期降低相关。修订版IPSET-thrombosis和ARTS评分有助于血栓风险分层。

要点

  • TN-ET患者中19.5%可检出致病/可能致病变异,突变者预后更差。
  • ASXL1、CBL、EZH2、ZRSR2突变与无白血病生存期较差相关。
  • 修订版IPSET-thrombosis和ARTS评分可分别优化整体及动脉血栓风险分层。

核心结论

  • TN-ET患者中致病/可能致病变异与白血病进展风险增加及总生存期降低独立相关。
  • 年龄>60岁、既往血栓史及心血管危险因素与血栓风险升高相关。

研究设计与样本

  • 回顾性研究纳入241例经骨髓活检证实且接受髓系基因panel测序的TN-ET患者。

主要发现

  • 19.5%的患者检出致病/可能致病变异。
  • 突变携带者中位年龄66岁 vs 53岁(p<0.001),既往血栓史19.6% vs 6.5%(p=0.013)。
  • 致病/可能致病变异与白血病进展相关(HR 12.608;95%CI 2.616-60.775,p=0.002)。
  • 致病/可能致病变异与总生存期降低相关(HR 3.008;95%CI 1.43-6.327,p=0.004)。
  • ASXL1(p=0.004)、CBL(p<0.001)、EZH2(p<0.001)、ZRSR2(p<0.001)突变与无白血病生存期较差相关。

关键数值与推荐

  • 修订版IPSET-thrombosis分层10年总体血栓概率:高危30%、中危15%、极低危6%(p<0.001)。
  • ARTS评分分层10年动脉血栓概率:高危25%、低危6%(p<0.001)。
  • 本队列中进展为骨髓纤维化罕见(2.5%)。

临床怎么用

  • 对TN-ET患者应进行髓系基因panel测序以识别高危突变并指导预后判断。
  • 采用修订版IPSET-thrombosis和ARTS评分分别评估总体及动脉血栓风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Triple-negative essential thrombocythemia (TN-ET) represents a diagnostic and therapeutic challenge. The aim of the present study was to identify prognostic factors useful for tailoring treatment. 241 TN-ET patients with myeloid panel sequencing and confirmatory bone marrow biopsy were selected. Pathogenic/likely pathogenic variants were identified in 19.5% of patients. Mutation carriers were older (median age 66 years vs. 53, p < 0.001) and had a higher frequency of prior thrombosis (19.6% vs. 6.5%, p = 0.013). Presence of pathogenic/likely pathogenic variants was associated with leukemic progression (HR 12.608; 95% CI: 2.616-60.775, p = 0.002) and lower overall survival (HR 3.008; 95% CI: 1.43-6.327, p = 0.004). ASXL1 (p = 0.004), CBL (p < 0.001), EZH2 (p < 0.001), and ZRSR2 (p < 0.001) mutations were associated with inferior leukemia-free survival. Age over 60 years, previous thrombosis, and cardiovascular risk factors were associated with higher thrombotic risk. Revised IPSET-thrombosis was useful for risk stratification (10-year probability of overall thrombosis: 30%, 15%, and 6% for high-, intermediate-, and very-low risk patients, respectively, p < 0.001). ARTS score refined arterial thrombosis stratification (10 years probability: 25% and 6% for high- and low-risk, respectively, p < 0.001). Progression to myelofibrosis was a rare event in this cohort (2.5%). These results highlight the biological and prognostic relevance of molecular profile in TN-ET.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Carreño-Tarragona G, Gil-Manso R, Hernández-Boluda JC, et al. Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia. Leukemia. 2026. PMID: 42443413. doi:10.1038/s41375-026-03035-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。